Cargando…
(131)I-Traced PLGA-Lipid Nanoparticles as Drug Delivery Carriers for the Targeted Chemotherapeutic Treatment of Melanoma
Herein, folic acid (FA) conjugated Poly(d,l-lactide-co-glycolide) (PLGA)-lipid composites (FA-PL) were developed as nanocarriers for the targeted delivery of insoluble anti-cancer drug paclitaxel (PTX), resulting FA-PLP nanoparticles. Furthermore, (131)I, as a radioactive tracer, was used to label F...
Autores principales: | Wang, Haiyan, Sheng, Weizhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438325/ https://www.ncbi.nlm.nih.gov/pubmed/28532129 http://dx.doi.org/10.1186/s11671-017-2140-7 |
Ejemplares similares
-
In vitro performance of lipid-PLGA hybrid nanoparticles as an antigen delivery system: lipid composition matters
por: Hu, Yun, et al.
Publicado: (2014) -
Novel preparation of PLGA/HP55 nanoparticles for oral insulin delivery
por: Wu, Zhi Min, et al.
Publicado: (2012) -
Oral Delivery of DMAB-Modified Docetaxel-Loaded PLGA-TPGS Nanoparticles for Cancer Chemotherapy
por: Chen, Hongbo, et al.
Publicado: (2010) -
Highly Stable PEGylated Poly(lactic-co-glycolic acid) (PLGA) Nanoparticles for the Effective Delivery of Docetaxel in Prostate Cancers
por: Cao, Long-Bin, et al.
Publicado: (2016) -
Antitumor Effect of (131)I-Labeled Anti-VEGFR2 Targeted Mesoporous Silica Nanoparticles in Anaplastic Thyroid Cancer
por: Zhang, Ruiguo, et al.
Publicado: (2019)